Samsung Life Science Fund Invests in U.S. Cartography Bioscience

Discovery of Tumor-Specific Antigens Using ATLAS and SUMMIT Platforms
Phase 1 Clinical Trial Underway for Colorectal Cancer T-Cell Engager 'CBI-1214'

Samsung Life Science Fund announced on May 7 that it has invested in the U.S. biotech venture Cartography Bioscience. The investment amount was not disclosed.

Cartography Bioscience Company Logo Image. Cartography Bioscience

The Samsung Life Science Fund is a venture capital fund jointly established by Samsung C&T, Samsung Biologics, and Samsung Bioepis, and is managed by Samsung Venture Investment. Cartography Bioscience is a company with an antigen discovery platform that combines single-cell gene data with bioinformatics (BI). Through its proprietary platforms 'ATLAS' and 'SUMMIT', the company identifies tumor-specific antigens and antigen combinations, and designs antibody therapeutics based on these findings.

The main pipeline is 'CBI-1214', a T-cell engager with an indication for colorectal cancer. The company entered Phase 1 clinical trials in early 2026 and is currently recruiting patients.

Jung Hyungnam, Executive Vice President and Head of Research at Samsung Biologics, stated, "Cartography is an innovative next-generation biotechnology company that can change the therapeutic paradigm by combining single-cell gene data and bioinformatics for each cancer type. We will continue to support innovative technologies that bring real changes for patients worldwide."

Kevin Parker, CEO of Cartography Bioscience, commented, "Samsung is the partner that best aligns with our mission to precisely analyze tumor biology and develop differentiated therapeutics."

This content was produced with the assistance of AI translation services.